Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Erythrocytes Used as Tumor Antigen Delivery System

Françoise Horand
Published: Monday, May 09, 2016



Françoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

The innovative approach of Erytech for in situ cancer immunotherapy is to use the property of erythrocytes to be naturally phagocytosed by antigen-presenting cells. Various tumoral antigen can efficiently be loaded into erythrocytes which serve as carrier to specifically deliver the tumor antigen to antigen-presenting cells. Following 2 injections, an efficient and specific immune response is induced, resulting in a significant delay of tumor growth in mouse tumor models of melanoma and prostate cancer.

This new approach of tumor antigen delivery systems to induce immune response can be a very promising strategy in cancer immunotherapy.


Françoise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

The innovative approach of Erytech for in situ cancer immunotherapy is to use the property of erythrocytes to be naturally phagocytosed by antigen-presenting cells. Various tumoral antigen can efficiently be loaded into erythrocytes which serve as carrier to specifically deliver the tumor antigen to antigen-presenting cells. Following 2 injections, an efficient and specific immune response is induced, resulting in a significant delay of tumor growth in mouse tumor models of melanoma and prostate cancer.

This new approach of tumor antigen delivery systems to induce immune response can be a very promising strategy in cancer immunotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x